PTC Therapeutics to buy ST-920 Fabry gene therapy for $111M
PTC Therapeutics agreed to buy Sangamo’s ST-920 Fabry gene therapy for $111M, with $100M in milestones.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.